Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

This study has been completed.
Sponsor:
Collaborator:
Department of Health, Western Australia
Information provided by (Responsible Party):
Amarillo Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT00895947
First received: May 6, 2009
Last updated: September 12, 2011
Last verified: September 2011
Results First Received: November 16, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Upper Respiratory Tract Infections
Interventions: Drug: interferon-alpha
Other: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 200 healthy volunteers were enrolled at the University of Western Australia in Perth between April 17 and July 31, 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Two of 200 randomized subjects (one in each group) decided not to begin study treatment after enrollment, so only 198 subjects were evaluable for response.

Reporting Groups
  Description
Interferon-alpha 150 international units of interferon-alpha given once daily for 16 weeks in an orally disolving lozenge consisting of 200 mg of anhydrous crystalline maltose
Placebo 200 mg anhydrous crystalline maltose given once daily for 16 weeks in an orally disolving lozenge

Participant Flow:   Overall Study
    Interferon-alpha     Placebo  
STARTED     100     100  
COMPLETED     88     90  
NOT COMPLETED     12     10  
Adverse Event                 3                 4  
Lost to Follow-up                 3                 4  
Protocol Violation                 4                 2  
Withdrawal by Subject                 2                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Interferon-alpha 150 international units of interferon-alpha given once daily for 16 weeks in an orally disolving lozenge consisting of 200 mg of anhydrous crystalline maltose
Placebo 200 mg anhydrous crystalline maltose given once daily for 16 weeks in an orally disolving lozenge
Total Total of all reporting groups

Baseline Measures
    Interferon-alpha     Placebo     Total  
Number of Participants  
[units: participants]
  100     100     200  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     95     91     186  
>=65 years     5     9     14  
Age  
[units: years]
Mean ± Standard Deviation
  45.0  ± 14.4     47.3  ± 13.2     46.2  ± 14.2  
Gender  
[units: participants]
     
Female     70     66     136  
Male     30     34     64  
Region of Enrollment  
[units: participants]
     
Australia     100     100     200  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Frequency of Influenza-like Illness   [ Time Frame: 16 weeks ]

2.  Secondary:   Symptom Incidence/Severity   [ Time Frame: 16 weeks ]

3.  Secondary:   Impact of Cold/Flu Symptoms   [ Time Frame: 16 weeks ]

4.  Secondary:   Negative Events Related to Cold/Flu Symptoms   [ Time Frame: 16 weeks ]

5.  Secondary:   Incidence/Severity of Viral Respiratory Infections   [ Time Frame: 16 weeks ]

6.  Post-Hoc:   Acute Respiratory Illness   [ Time Frame: 16 weeks ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Martin J. Cummins
Organization: Amarillo Biosciences, Inc.
phone: 806-376-1741 ext 14
e-mail: mcummins@amarbio.com


No publications provided


Responsible Party: Amarillo Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT00895947     History of Changes
Other Study ID Numbers: 2008-113
Study First Received: May 6, 2009
Results First Received: November 16, 2010
Last Updated: September 12, 2011
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration